Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 374537-97-0 | MDL No. : | MFCD02093947 |
Formula : | C7H9BrN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | YAVKJNIMFGZBSY-UHFFFAOYSA-N |
M.W : | 201.06 | Pubchem ID : | 7010307 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.29 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 46.27 |
TPSA : | 38.91 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.16 cm/s |
Log Po/w (iLOGP) : | 1.89 |
Log Po/w (XLOGP3) : | 1.92 |
Log Po/w (WLOGP) : | 2.05 |
Log Po/w (MLOGP) : | 1.65 |
Log Po/w (SILICOS-IT) : | 2.2 |
Consensus Log Po/w : | 1.94 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.74 |
Solubility : | 0.366 mg/ml ; 0.00182 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.36 |
Solubility : | 0.876 mg/ml ; 0.00436 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.3 |
Solubility : | 0.101 mg/ml ; 0.000504 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.75 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | |
Hazard Statements: | H302 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In N,N-dimethyl-formamide; at 80℃; for 2h; | To a solution of 1,1-dimethylethyl (2S)-2-(3-bromo-2-oxopropyl)-1-piperidinecarboxylate D2 (0.13 g, 0.39 mmol) in DMF (1 ml), <strong>[374537-97-0]5-bromo-3,4-dimethyl-2-pyridinamine</strong> (0.12 g, 0.59 mmol) was added and the mixture heated at 80 C. for 2 h. The reaction was eluted through a SCX column. Collected fractions gave 0.13 g of an oil containing a mixture of the final compound, the corresponding N-Boc protected derivative and some residual <strong>[374537-97-0]5-bromo-3,4-dimethyl-2-pyridinamine</strong>. [N-Boc derivative data: MS: (ES/+) m/z: 422 (M+1, 100%) and 424 (M+1, 100%). C20H28BrN3O2 requires 421]. The crude was dissolved in DCM (2.50 ml) and the resulting solution cooled to 0 C. TFA (0.50 ml) was added dropwise, the reaction left under stirring for 1 h and then eluted through a SCX column. Collected fractions gave the title compound D16 (0.090 g, 0.28 mmol, 72% yield from D2, two steps). MS: (ES/+) m/z: 322 (M+1, 100%) and 324 (M+1, 100%). C15H20BrN3 requires 321. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62% | With sulfuric acid; sodium nitrite; In water; at 0 - 31℃; for 0.5h; | To a mixture of <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (0.6 g, 3.0 mmol) and H2SO4 (98%, 1.62 mL) and H2O (18 mL) is added a solution of NaNO2 (243.6 mg, 4.2 mmol) in H2O (1.6 mL) drop-wise at 0 C. Then, it was stirred at 31 C. for 30 minutes and filtered. The resulting solid is washed with water to provide the title compound (375.0 mg, 62%) as a white solid. 1H NMR (CDCl3, 400 MHz) delta 7.48 (s, 1H), 2.32 (s, 3H), 2.19 (s, 3H). LCMS (M+H)+ 202. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
12.16% | A mixture of <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (1.0 g, 4.97 mmol), tert-butyl 3-oxopiperidine-1-carboxylate (0.991 g, 4.97 mmol), and acetic acid (0.028 mL, 0.497 mmol) in toluene (100 mL) was heated to reflux. Water was azeotroped using a Dean15 Stark apparatus. The mixture was heated at reflux for 2 days. After cooling to roomtemperature, air was bubbled through the reaction mixture for 2 h to promote oxidative dehydrogenation. The resulting solution was concentrated under high vacuum to afford a viscous oil. The oil was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution. The aqueous portion was back extracted with ethyl acetate.The combined organic portions were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified twice using silica gel column chromatography (100% EtOAc) to afford butyl 8-bromo-6,7-dimethyl-3,4- dihydroimidazo [1,2-a: 5,4-b?j dipyridine- 1 (2H)-carboxylate (242 mg, 0.605 mmol, 12.16% yield). LC/MS (M+H) 380.1, 382.1. ?HNMR(500MHz, chloroform-d) oe 8.06 (s, 1H),A mixture of <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (1.0 g, 4.97 mmol), tert-butyl 3-oxopiperidine-1-carboxylate (0.991 g, 4.97 mmol), and acetic acid (0.028 mL, 0.497 mmol) in toluene (100 mL) was heated to reflux. Water was azeotroped using a Dean15 Stark apparatus. The mixture was heated at reflux for 2 days. After cooling to roomtemperature, air was bubbled through the reaction mixture for 2 h to promote oxidative dehydrogenation. The resulting solution was concentrated under high vacuum to afford a viscous oil. The oil was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution. The aqueous portion was back extracted with ethyl acetate.The combined organic portions were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified twice using silica gel column chromatography (100% EtOAc) to afford butyl 8-bromo-6,7-dimethyl-3,4- dihydroimidazo [1,2-a: 5,4-b?j dipyridine- 1 (2H)-carboxylate (242 mg, 0.605 mmol, 12.16% yield). LC/MS (M+H) 380.1, 382.1. ?HNMR(500MHz, chloroform-d) oe 8.06 (s, 1H) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
92% | <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (5.00 g, 24.87 mmol), DMF (10 mL) and Nu,Nu-dimethylformamide dimethyl acetal (11.15 mL, 83 mmol). The vial was heated to 80 C for 6 hours. The vial was cooled to room temperature. The volatiles were removed under vacuum and the resulting oil was dissolved in MeOH (5 mL) and pyridine (3.02 mL, 37.3 mmol) and cooled to 0 C. Hydroxylamine-O-sulfonic acid (4.22 g, 37.3 mmol) was added over 15 minutes and the mixture allowed to warm to room temperature overnight. The solution was concentrated under vacuum. The resulting white solid was partitioned between EtOAc and 1.5 M potassium phosphate solution. The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x50 mL). The combined organics were washed with water (50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and concentrated to give a white solid. The solid was dissolved in DCM and MeOH and charged to an 80G silica gel column which was eluted with 0-100% ethyl acetate/hexane. Following concentration of the fractions, 6-bromo-7,8-dimethyl-[l,2,4]triazolo[l,5-a]pyridine (5.2 g, 23.00 mmol, 92 % yield) was collected as a whitish solid. LC-MS: M+l= 226/228, rt = 0.75 min, [Al]; NMR: NMR (400 MHz, CHLOROFORM-d) delta 8.68 (s, 1H), 8.26 (s, 1H), 2.68 (s, 3H), 2.50 (s, 3H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
66.3% | With sulfuric acid; sodium nitrite; In water; at 0 - 20℃; for 1h; | To a mixture of <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (0.6 g, 2.98 mmol) in concentrated H2SO4 (2 mL) and water (15 mL) was added a solution of sodium nitrite (0.309 g, 4.48 mmol) in water (1.5 mL) at 0 C. The mixture was allowed to equilibrate to room temperature and stirred for 1 h. The precipitate was filtered and washed with water and dried to afford 5-bromo-3,4-dimethylpyridin-2-ol (400 mg, 1.980 mmol, 66.3 % yield), m/z (203, M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
64.7% | With hydrogenchloride; sodium nitrite; at -15 - 25℃; for 16h; | Procedure B: <strong>[374537-97-0]5-bromo-3,4-dimethylpyridin-2-amine</strong> (1.00 g, 4.97 mmol) was suspended in concentrated hydrochloric acid (23 mL) and was cooled to -15 C. Sodium nitrite (1.72 g, 24.9 mmol) was added slowly and the reaction mixture was slowly warmed to 25 C. After 16 hours, the reaction was quenched by addition of water and dichloromethane. The layers were separated, and the aqueous layer was extracted with dichloromethane (3 x 25 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to afford a crude orange solid. This crude material was purified by silica gel chromatography eluting with hexanes/EtOAc 100/0 to 0/100. Following concentration of the fractions, the product was isolated as a clear oil 5-bromo-2-chloro-3,4- dimethylpyridine (709 mg, 3.22 mmol, 64.7 % yield). LC retention time 0.97 min [TS 1]. |
[ 959558-28-2 ]
4-Bromo-2,7-naphthyridin-1-amine
Similarity: 0.93
[ 98198-48-2 ]
2-Amino-5-bromo-4-methylpyridine
Similarity: 0.92
[ 3430-21-5 ]
5-Bromo-3-methylpyridin-2-amine
Similarity: 0.92
[ 443956-55-6 ]
2-Amino-5-bromo-3-(hydroxymethyl)pyridine hydrobromide
Similarity: 0.83
[ 959558-28-2 ]
4-Bromo-2,7-naphthyridin-1-amine
Similarity: 0.93
[ 98198-48-2 ]
2-Amino-5-bromo-4-methylpyridine
Similarity: 0.92
[ 3430-21-5 ]
5-Bromo-3-methylpyridin-2-amine
Similarity: 0.92
[ 443956-55-6 ]
2-Amino-5-bromo-3-(hydroxymethyl)pyridine hydrobromide
Similarity: 0.83
[ 98198-48-2 ]
2-Amino-5-bromo-4-methylpyridine
Similarity: 0.92
[ 3430-21-5 ]
5-Bromo-3-methylpyridin-2-amine
Similarity: 0.92
[ 335031-01-1 ]
2-Amino-5-bromo-3-(hydroxymethyl)pyridine
Similarity: 0.83
[ 443956-55-6 ]
2-Amino-5-bromo-3-(hydroxymethyl)pyridine hydrobromide
Similarity: 0.83
[ 1210838-82-6 ]
5-Bromo-3-ethynylpyridin-2-ylamine
Similarity: 0.81